Cancer Therapies, Cancer Types, and Hematologic Malignancies

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/31

flashcard set

Earn XP

Description and Tags

Practice vocabulary flashcards covering cancer therapies, solid tumors, leukemias, lymphomas, and normal cell regulation based on lecture notes.

32 Terms

1
New cards

Tamoxifen

An estrogen receptor blocker used in cancer therapy.

2
New cards

Herceptin

A monoclonal antibody conjugated to a drug that blocks HER2.

3
New cards

Engineered protein therapy

A cancer therapy modality utilizing antibody-drug conjugates.

4
New cards

PARP inhibitors

Therapeutic agents that disrupt PARP repair of single-strand breaks and release chemotherapy payloads.

5
New cards

Sofosbuvir, ribavirin, and simeprevir

Small molecule inhibitors targeting HCV polymerase and protease.

6
New cards

Recombivax

A VLP-based vaccine developed against HBV.

7
New cards

Moderna personalized mRNA vaccine

An mRNA vaccine designed to recognize patient-specific neoantigens and activate T cells.

8
New cards

Darax unrasib

A small molecule that binds to cyclophilin A, which subsequently binds and inhibits Ras.

9
New cards

Gleevec

A small molecule inhibitor targeting the BCR-ABL fusion kinase.

10
New cards

CAR-T therapy

A treatment using engineered patient T cells that express a synthetic antigen receptor to redirect T cell killing.

11
New cards

Keytruda

A therapeutic antibody that prevents the deactivation of T cells by blocking the PD-1 receptor.

12
New cards

Breast ductal adenocarcinoma

A form of breast cancer originating in ductal epithelial cells, categorized into subtypes including ER+ER^+ Lum A, ER+ER^+ Lum B, HER2+, and triple-negative.

13
New cards

Hepatocellular carcinoma (HCC)

A liver cancer originating from hepatocytes and caused by HBV (DNA), HCV (RNA), or alcohol/habits, where hepatocytes die due to T cells rather than direct viral action.

14
New cards

Activating CTNNB1 mutations

Mutations located in phosphorylation sites of β-catenin\beta\text{-catenin} in hepatocellular carcinoma that prevent degradation and constitutively activate Wnt signaling.

15
New cards

Melanoma

A malignancy arising from melanocytes, categorized into subtypes including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma.

16
New cards

Benign nevus

An early melanocytic lesion characterized by MAPK pathway mutations such as BRAF or NRAS.

17
New cards

Intermediate lesion (Melanoma)

A melanocytic lesion characterized by the addition of TERT mutations to pre-existing MAPK mutations, after which no clear pathway progression exists.

18
New cards

Pancreatic ductal adenocarcinoma (PDAC)

A pancreatic cancer originating from ductal epithelial cells via acinar-to-ductal metaplasia, featuring early and frequent KRAS mutations in 90%90\% of cases.

19
New cards

Lung adenocarcinoma

A lung cancer subtype accounting for 40–50%40\text{--}50\% of cases, originating from alveolar type 2 (AT2) and/or distal airway progenitor cells, with early alterations in EGFR/KRAS and MAP kinase inducers.

20
New cards

Squamous cell lung carcinoma

A lung cancer subtype accounting for 20–30%20\text{--}30\% of cases, originating from basal cells of the proximal airway epithelium, characterized by early TP53 mutations.

21
New cards

Small-cell lung cancer (SCLC)

An aggressive lung malignancy accounting for 10–15%10\text{--}15\% of cases, originating from pulmonary neuroendocrine cells, driven by early loss of both TP53 and RB1.

22
New cards

Large cell lung carcinoma

A lung cancer subtype accounting for <5%<5\% of cases with an uncertain cell of origin, displaying no clear pathway to metastasis and a mix of TP53 and KRAS mutations.

23
New cards

Chronic myeloid leukemia (CML)

A leukemia arising from hematopoietic stem cells, driven by a BCR-ABL1 chromosomal translocation providing a constitutive growth signal.

24
New cards

Chronic phase of CML

The initial phase of chronic myeloid leukemia characterized solely by BCR-ABL mutations.

25
New cards

Blast phase of CML

The accelerated, acute phase of chronic myeloid leukemia in which 92%92\% of patients acquire additional genetic mutations.

26
New cards

Acute promyelocytic leukemia (APL)

A leukemia originating from myeloid progenitor cells (promyelocytes) driven by a PML-RARA translocation that causes differentiation arrest while cells remain cycling.

27
New cards

Burkitt lymphoma (BL)

A lymphoma arising from germinal center B cells (centroblasts), driven by MYC activation through Ig-MYC translocation alongside EBV infection, resulting in increased proliferation with high cyclin D.

28
New cards

Follicular lymphoma (FL)

A lymphoma arising from germinal center B cells (centrocytes), driven by the translocation of BCL2 behind a strong Ig promoter, causing BCL2 activation and resistance to apoptosis.

29
New cards

Multiple Myeloma (MM)

A cancer of terminally differentiated B cells (plasma cells) driven by extensive mutations, cyclin D amplification, growth factor amplification, and chromosomal alterations leading to plasma cell expansion and survival.

30
New cards

Phases of normal hepatocyte repair

A three-step regenerative pathway comprising: 1. Prime (prepare to proliferate), 2. Proliferate (repair mediated by Ras, PI3K, Wnt, or YAP/TAZ), and 3. Terminate (cessation of proliferation mediated by TGF-β\beta via p21, p27, and p15).

31
New cards

Melanocyte regulatory signaling

Signaling networks where slowly turning over melanocytes use β-catenin\beta\text{-catenin} for survival, MAPK (ERK/PI3K) for proliferation, and α-MSH\alpha\text{-MSH} to elevate cAMP\text{cAMP} for cell survival.

32
New cards

Chimeric Antigen Receptor (CAR) design workflow

A five-stage process comprising: sequencing the target, identifying cell surface proteins, designing a specific receptor, delivering it to T cells, and redirecting T cells against tumors.